Biogen Suggests EU Won’t Approve Alzheimer’s Drug A report in the New York Situations notes Biogen may well not be anticipating drug reviewers in the European Union to approve its Alzheimer’s drug Aduhelm — presently authorized, controversially, in the U.S. Meanwhile Aetna sues covid tests …